The cost-effectiveness of nationwide breast carcinoma screening in Finland, 1987-1992

BACKGROUND. The aim of this study was to evaluate the cost-effectiveness, f rom a societal perspective, of the Finnish nationwide breast carcinoma scre ening program. METHODS. The effects were measured in life-years saved from 1987 to 2020, u sing data from the nationwide program to the end of 1992. A total of 90,000 women ages 50-59 were invited for screening during the years 1987-89. The total number of participants screened was 76,000. The screening interval wa s 24 months, with follow-up to the end of 1992. From the beginning of 1993, the estimation model used parameters based on published studies and nation al cancer statistics. Data on health care and non-health care costs and tim e costs were obtained from internal accounts of screening units, published studies, national statistics, health market sources, and a questionnaire co mpleted by a sample of 1400 screening attendees. The discount rate, the ann ual rate of time preference over future costs and life-years saved, was 3%. The main outcome measure was the cost per life-year saved. RESULTS. The estimated number of life-years of life saved was 578, of which 8% occurred 1987-1992. The estimated life-years saved per 1000 screenings was 3.2. The total costs were $11 million in U.S. dollars, i.e., $14.3 mill ion per 100,000 participants. CONCLUSIONS. The cost of breast carcinoma mammographic screening per life-y ear saved was $18,955 in the base case, ranging from $15,502 to $40,308 acc ording to the different models used in analysis. Cancer 1999;86:638-46. (C) 1999 American Cancer Society.